Literature DB >> 3257879

Pharmacokinetics of propofol (diprivan) in elderly patients.

T Kirkpatrick1, I D Cockshott, E J Douglas, W S Nimmo.   

Abstract

The pharmacokinetics of propofol (2,6 diisopropylphenol) were compared in 12 patients aged 65-80 yr and 12 patients aged 18-35 yr. After premedication with papaveretum i.m., anaesthesia was induced with propofol 2.0 mg kg-1 in the elderly and 2.5 mg kg-1 in the younger patients. Alcuronium 12-20 mg was then given and the patient's lungs ventilated with halothane and nitrous oxide in oxygen. Blood was taken after various time intervals up to 24 h for the measurement of propofol concentrations by HPLC and for the estimation of propofol protein binding. The mean blood propofol concentration was generally higher in the elderly group, but this difference was only significant at 2 min after induction. The clearance of propofol was significantly lower in the elderly (1.44 +/- 0.10 (SE) litre min-1) than in the younger patients (1.79 +/- 0.12 litre min-1). The volume of the central compartment in the elderly patients was significantly smaller (19.6 +/- 5.2 litre) than that in the young (26.3 +/- 2.9 litre). There was no difference in the volume of distribution at equilibrium (1608 +/- 246 litre in the elderly and 1757 +/- 360 litre in the young), in the volume of distribution at steady state (691 +/- 139 litre in the elderly and 771 +/- 236 litre in the young) or in the half-lives of distribution and elimination. The plasma protein binding of propofol was similar in both groups and showed no trend with time after dose.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257879     DOI: 10.1093/bja/60.2.146

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  37 in total

Review 1.  Acute pancreatitis after single-dose exposure to propofol: a case report and review of literature.

Authors:  Qaiser Jawaid; Michael E Presti; Brent A Neuschwander-Tetri; Frank R Burton
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

2.  Propofol increases the rate of albumin-unbound free midazolam in serum albumin solution.

Authors:  Jun Ohmori; Shigeru Maeda; Hitoshi Higuchi; Minako Ishii; Yukiko Arai; Yumiko Tomoyasu; Atsushi Kohjitani; Masahiko Shimada; Takuya Miyawaki
Journal:  J Anesth       Date:  2011-06-01       Impact factor: 2.078

Review 3.  Contemporary intravenous anesthetic agents and delivery systems: propofol.

Authors:  R M Peskin
Journal:  Anesth Prog       Date:  1992

Review 4.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

5.  Propofol attenuates angiotensin II-induced vasoconstriction by inhibiting Ca2+-dependent and PKC-mediated Ca 2+ sensitization mechanisms.

Authors:  Toshiyuki Kuriyama; Yasuyuki Tokinaga; Kazuaki Tange; Yoshiki Kimoto; Koji Ogawa
Journal:  J Anesth       Date:  2012-05-29       Impact factor: 2.078

Review 6.  Anaesthesia in the elderly. Special considerations.

Authors:  A G Jones; J M Hunter
Journal:  Drugs Aging       Date:  1996-11       Impact factor: 3.923

7.  Total body propofol clearance (TBPC) after living-donor liver transplantation (LDLT) surgery is decreased in patients with a long warm ischemic time.

Authors:  Wael S Al-Jahdari; Fumio Kunimoto; Shigeru Saito; Koujirou Yamamoto; Hiroshi Koyama; Ryuya Horiuchi; Fumio Goto
Journal:  J Anesth       Date:  2006       Impact factor: 2.078

Review 8.  Propofol in patients with cardiac disease.

Authors:  N R Searle; P Sahab
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

Review 9.  Clinically important drug interactions with intravenous anaesthetics in older patients.

Authors:  Helge Eilers; Claus Niemann
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Kinetics of nicotinic acetylcholine ion channels in the presence of intravenous anaesthetics and induction agents.

Authors:  R E Wachtel; E S Wegrzynowicz
Journal:  Br J Pharmacol       Date:  1992-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.